From GlobeNewswire: 2025-02-07 16:30:00

Tempest Therapeutics, Inc. granted one employee 45,000 nonqualified stock options under the 2023 Inducement Plan. The options will vest over four years, with 25% vesting on the first anniversary of employment and the rest monthly. Tempest is a biotech company developing cancer therapeutics with tumor-targeted and immune-mediated mechanisms. Headquartered in Brisbane, California, Tempest has ongoing global studies in first-line cancer treatment. For more information, visit their website. Investor and media inquiries can be directed to Sylvia Wheeler and Aljanae Reynolds at Wheelhouse Life Science Advisors. Approval by the FDA is pending for Tempest’s products.



Read more at GlobeNewswire: Tempest Reports Inducement Grant Under Nasdaq Listing Rule